Filing Flows

Filing Flows › Companies › Angiodynamics › Cash flow

Angiodynamics cash flow, quarter by quarter

Latest: Q1 FY27 · from the cash-flow statements filed with the SEC

Free cash flow−$15.7M in Q1 FY27 · $1.4M over twelve months

Operating cash flow−$15.3M
Capital spending−$379K
Free cash flow−$15.7M
Cash conversion cycle122 days

Analysis

In Q1 FY27, Angiodynamics generated −$15.3M of operating cash flow and spent $379K on capital projects, leaving free cash flow of −$15.7M. That is $936K more than in Q1 FY26 (−$16.6M).

Over the twelve months to Aug 31, 2026, operating cash flow was $3.7M; the largest uses were other investing ($5.3M), capital spending ($2.2M), other financing ($571K); the cash balance fell by $4.8M.

Operating cash flow was −$15.3M against net income of −$7.1M. The largest differences: payables −$17.4M, depreciation & amortization +$5.5M, stock-based pay +$4.5M.

Its cash conversion cycle was 122 days (receivables 53 + inventory 150 − payables 81).

Free cash flow

Angiodynamics: free cash flow by quarterAngiodynamics: free cash flow by quarter$1.7MQ2 FY25−$15.0MQ3 FY25$18.0MQ4 FY25−$16.6MQ1 FY26$4.2MQ2 FY26−$4.1MQ3 FY26$17.0MQ4 FY26−$15.7MQ1 FY27
Operating cash flow less capital spending.
Angiodynamics: operating cash flow against capital spendingAngiodynamics: operating cash flow against capital spendingOperating cash flowCapital spending$2.5M$797KQ2 FY25−$13.2M$1.8MQ3 FY25$18.8M$777KQ4 FY25−$15.9M$731KQ1 FY26$4.7M$422KQ2 FY26−$3.1M$1.0MQ3 FY26$17.5M$413KQ4 FY26−$15.3M$379KQ1 FY27
Latest (Q1 FY27): Operating cash flow −$15.3M, Capital spending $379K.

Capital allocation, year by year

Angiodynamics: where the cash came from (up) and went (down), by fiscal yearAngiodynamics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingBuybacksFY22: Operating cash flow −$7.2MFY22: Net borrowing $5.0MFY22: Shares issued $2.7MFY22: Capital spending −$4.3M$7.7MFY22FY23: Operating cash flow $78KFY23: Net borrowing −$45.0MFY23: Shares issued $300KFY23: Capital spending −$3.8M$378KFY23FY24: Operating cash flow −$28.2MFY24: Net borrowing −$50.0MFY24: Asset sales $134MFY24: Capital spending −$2.5M$134MFY24FY25: Operating cash flow −$10.1MFY25: Net borrowing $6.2MFY25: Shares issued $200KFY25: Capital spending −$4.5MFY25: Buybacks −$1.7M$6.4MFY25FY26: Operating cash flow $3.1MFY26: Net borrowing −$375KFY26: Capital spending −$2.6M$3.1MFY26
Over these 5 years operating cash flow totalled −$42.3M; the largest uses were net borrowing ($95.4M) and operating cash flow ($45.5M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$34.0M
Debtnone
Net cash$34.0M
Cash runway6 months

Angiodynamics is burning cash: its operations consume cash, a free cash flow of −$62.8M a year at the current rate against $34.0M of cash and investments: a runway of about 6 months before any new financing.

Where the cash came from and went

Angiodynamics: sources (+) and uses (−) of cash, Q1 FY27Angiodynamics: sources (+) and uses (−) of cash, Q1 FY27Cash drawn (+) / kept (−)$19.9MOperating cash flow−$15.3MOther investing−$2.8MShares issued−$1.3MCapital spending−$379KNet borrowing (+) / repaid (−)−$99KExchange rates−$38K
Angiodynamics: sources (+) and uses (−) of cash, TTM to Q1 FY27Angiodynamics: sources (+) and uses (−) of cash, TTM to Q1 FY27Other investing−$5.3MCash drawn (+) / kept (−)$4.8MOperating cash flow$3.7MCapital spending−$2.2MOther financing−$571KNet borrowing (+) / repaid (−)−$383KExchange rates$38K

From profit to cash

Angiodynamics: net income to operating cash flow, Q1 FY27Angiodynamics: net income to operating cash flow, Q1 FY27Net income−$7.1MDepreciation & amortization$5.5MStock-based pay$4.5MDeferred taxes−$306KOther non-cash−$707KReceivables$3.5MInventory−$2.7MPayables−$17.4MPrepaid and other assets−$1.0MOperating cash flow−$15.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q1 FY275315081122
Q4 FY265012870108
Q3 FY265215179124
Q2 FY265016888129
Q1 FY265216989132
Q4 FY255015277124
Q3 FY255417588141
Q2 FY255218091141

Every quarter

QuarterOperating cash flowCapital spendingBuybacksNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q1 FY27−$15.3M−$379K—−$99K−$1.3M$19.9M−$15.7M
Q4 FY26$17.5M−$413K—−$97K—−$16.1M$17.0M
Q3 FY26−$3.1M−$1.0M—−$95K$716K$3.8M−$4.1M
Q2 FY26$4.7M−$422K—−$92K—−$2.9M$4.2M
Q1 FY26−$15.9M−$731K—−$91K$234K$17.1M−$16.6M
Q4 FY25$18.8M−$777K—−$90K—−$11.1M$18.0M
Q3 FY25−$13.2M−$1.8M—−$58K$895K$9.3M−$15.0M
Q2 FY25$2.5M−$797K−$1.1M—−$5K$916K$1.7M

Angiodynamics: income statement and cash flow

Angiodynamics, Q1 FY27: revenue $80.9M (+7% year over year), operating margin -9.0%. The chart follows the revenue to costs, profit and cash.

Angiodynamics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.